Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603122 vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Cowealth Medical China Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cowealth Medical China Co Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cowealth Medical China Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Cowealth Medical China Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cowealth Medical China Co (SHSE:603122) has a Buyback Yield % of 0.00 as of Aug. 13, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cowealth Medical China Co and its competitors. According to the industry distribution chart, Cowealth Medical China Co ranks #999999 out of 83 companies in the Medical Diagnostics & Research industry.
Is Cowealth Medical China Co's Buyback Yield % too high?
Cowealth Medical China Co's current Buyback Yield % is 0.00. Based on the distribution chart, Cowealth Medical China Co ranks #999999 out of 83 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Cowealth Medical China Co has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cowealth Medical China Co's Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cowealth Medical China Co ranks #999999 out of 83 companies for Buyback Yield %. This places Cowealth Medical China Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cowealth Medical China Co and its competitors. Cowealth Medical China Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cowealth Medical China Co stock overvalued right now?
Based on GuruFocus' analysis, Cowealth Medical China Co (SHSE:603122) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.80, compared to a current price of ¥12.50 — trading 228.9% above its estimated fair value. The current Buyback Yield % is 0.00. Cowealth Medical China Co's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cowealth Medical China Co (SHSE:603122), the current Buyback Yield % is 0.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cowealth Medical China Co (SHSE:603122) Overvalued in 2026?
Based on GuruFocus' analysis, Cowealth Medical China Co stock appears to be overvalued.
The current stock price of ¥12.50 is trading 228.9% above its estimated GF Value™ of ¥3.80.
GuruFocus considers Cowealth Medical China Co to be Significantly Overvalued.
Key valuation signals for SHSE:603122:
Buyback Yield %: 0.00
GF Value™: ¥3.80 vs. price of ¥12.50 (228.9% above fair value)
No single metric tells the full story. See the SHSE:603122 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603122 has been successfully added to your 
